Home › Funds › Octagon Capital Advisors LP › DBVT
Octagon Capital Advisors LP position in DBVT
DBV TECHNOLOGIES S A · Health Care
Octagon Capital Advisors LP reported holding 574,200 shares of DBVT (DBV TECHNOLOGIES S A) in its Q3 2026 13F filing — a position valued at US$6.8M, representing 0.90% of its reported portfolio and ranking #20 among its reported holdings. Octagon Capital Advisors LP has disclosed DBVT holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Octagon Capital Advisors LP's DBVT position evolved
Octagon Capital Advisors LP first disclosed a stake in DBVT in Q2 2025 at 1,018,021 shares (US$9.3M). The position peaked in Q1 2026 at 574,200 shares, worth US$12.0M. Across 6 filings, Octagon Capital Advisors LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 574,200 shares valued at US$6.8M. Notable position changes include a 44% trim in Q4 2025 (shares rose 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.02M | $9.31M | New |
| Q3 2025 | 1.02M | $10.18M | Hold |
| Q4 2025 | 574.20K | $11.01M | Reduce |
| Q1 2026 | 574.20K | $12.00M | Hold |
| Q2 2026 | 574.20K | $9.42M | Hold |
| Q3 2026 | 574.20K | $6.75M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DBVT and 13F data
DBVT (DBV TECHNOLOGIES S A) is a Health Care company. 44 other funds we track also report a position in DBVT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$43.0M), MPM BioImpact LLC (US$35.8M), Siren, L.L.C. (US$27.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DBVT
- RA CAPITAL MANAGEMENT, L.P. 3.66M sh · $43.01M · Q3 2026
- MPM BioImpact LLC 3.04M sh · $35.81M · Q3 2026
- Siren, L.L.C. 2.36M sh · $27.71M · Q3 2026
- ADAR1 Capital Management, LLC 2.01M sh · $23.65M · Q3 2026
- Vivo Capital, LLC 1.84M sh · $21.69M · Q3 2026
- BAKER BROS. ADVISORS LP 1.46M sh · $17.19M · Q3 2026
- Patient Square Capital LP 1.11M sh · $13.00M · Q3 2026
- Redmile Group, LLC 373.42K sh · $4.39M · Q3 2026
- Ishara Investments LP 270.00K sh · $3.18M · Q3 2026
- Elmind Capital, LP 265.00K sh · $3.12M · Q3 2026
- GREAT POINT PARTNERS LLC 250.00K sh · $2.94M · Q3 2026
- Yiheng Capital Management, L.P. 170.14K sh · $2.00M · Q3 2026
More on Octagon Capital Advisors LP
FAQ
How long has Octagon Capital Advisors LP held DBVT?
Octagon Capital Advisors LP has disclosed DBVT holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Octagon Capital Advisors LP's current position in DBVT?
As of Q3 2026, Octagon Capital Advisors LP holds 574.20K shares of DBVT (DBV TECHNOLOGIES S A), valued at $6.75M, representing 0.90% of its reported portfolio and ranking #20.
Has Octagon Capital Advisors LP been buying or selling DBVT?
In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP held unchanged its position in DBVT. The position peaked in Q1 2026 at 574.20K shares.
Which other funds hold DBVT?
Other major institutional holders of DBVT include RA CAPITAL MANAGEMENT, L.P., MPM BioImpact LLC, Siren, L.L.C., among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.